Stay Up
to Date
Stay Up
to Date
Breaking News,
Updates, & More
Breaking News,
Updates, & More
Click Here to
Subscribe
Click Here to
Subscribe

Diagnostic Imaging Agent FDA Approved for Rare Neuroendocrine Tumors

TON July 2016 Vol 9 No 4 - FDA Approvals

Diagnostic Imaging Agent FDA Approved for Rare Neuroendocrine Tumors

According to a recent announcement by the US Food and Drug Administration (FDA), Netspot, a radioactive diagnostic agent for positron emission tomography (PET) imaging, has been approved in adult and pediatric patients with somatostatin receptor–positive neuroendocrine tumors.

The agent—gallium Ga-68 dotatate—is a positron-emitting analogue of so­matostatin, a hormone that regulates the endocrine system. Neuroendocrine tumors have receptors for this hormone, and gallium Ga-68 dotatate works by binding to them.

This FDA approval was based on 3 studies evaluating the safety and efficacy of Netspot, all of which confirmed the usefulness of Ga-68 dotatate images in locating neuroendocrine tumors.

Netspot is supplied as a sterile, single-dose kit, for preparation of a Ga-68 dotatate intravenous injection; serious adverse reactions have not been identified with use of this agent.

Reference

US Food and Drug Administration. FDA approves new diagnostic imaging agent to detect rare neuroendocrine tumors. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm504524.htm. Published June 1, 2016. Accessed June 22, 2016.

Return to Top


Diagnostic Blood Test FDA Approved for NSCLC Gene Mutation

The Cobas EGFR (epidermal growth factor receptor) Mutation Test v2 is the first blood-based genetic test approved by the FDA for detecting EGFR gene mutation in patients with non–small-cell lung cancer (NSCLC). This test is a companion diagnostic for erlotinib (Tarceva; Astellas Pharma US, Inc, and Genentech, Inc).

"Approvals of liquid biopsy tests make it possible to deliver highly individualized health care for patients," explained Alberto Gutierrez, PhD, Director, Office of In Vitro Diagnostics and Radiological Health, FDA Center for Devices and Radiological Health, Silver Spring, MD, in a press release by the organization.

The test can detect the presence of specific NSCLC mutations in patients' blood samples, and help select those who may benefit from treatment with erlotinib. A tumor biopsy should be performed to determine whether mutations are present if they are not detected in the blood, the FDA noted.

The efficacy of the Cobas EGFR Mutation Test v2 was evaluated among patients in a clinical trial whose tumor biopsies were previously confirmed as positive for the EGFR exon 19 deletion or L858R mutations.

Reference

US Food and Drug Administration. FDA approves first blood test to detect gene mutation associated with non-small cell lung cancer. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm504488.htm. Published June 1, 2016. Accessed June 22, 2016.

Return to Top


Axumin FDA Approved for Recurrent Prostate Cancer

With prostate cancer the second leading cause of cancer-related death among US men, accurate staging is paramount in improving management and outcome among patients with suspected cancer recurrence after their primary treatment.

In a recent announcement, the FDA has stated its approval of axumin, an injectable radioactive agent. Axumin is indicated for PET imaging in men with suspected cancer recurrence, based on elevated prostate-specific antigen levels following prior treatment.

This approval was based on data from 2 studies that evaluated the safety and efficacy of axumin for imaging prostate cancer in patients with recurrent disease. The most commonly reported side effects among patients receiving axumin were pain and redness at the injection site, and a metallic taste in the mouth.

Reference

US Food and Drug Administration. FDA approves new diagnostic imaging agent to detect recurrent prostate cancer. www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm503920.htm. Published May 27, 2016. Accessed June 22, 2016.

Return to Top

Related Items
Keytruda Approved for Patients with Previously Treated Metastatic Small-Cell Lung Cancer
Yvette Florio Lane
Web Exclusives published on June 26, 2019 in FDA Approvals, In the News
FDA News
TON - June 2019, Vol 12, No 3 published on June 17, 2019 in FDA Approvals
First Chemoimmunotherapy Regimen Granted Accelerated Approval for Patients with Previously Treated DLBCL
Yvette Florio Lane
Web Exclusives published on June 12, 2019 in FDA Approvals, In the News
Welcome to the Fourth Annual Oncology Guide to New FDA Approvals
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in FDA Approvals
New Indications Approved by the FDA in 2018 for Oncology Drugs
Dalia Buffery, MA, ABD
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in FDA Approvals
FDA Approvals of Novel Brand-Name Prescription Cancer Drugs in 2018
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in FDA Approvals
Braftovi (Encorafenib) plus Mektovi (Binimetinib) Third BRAF/MEK Inhibition Combination Approved for Metastatic Melanoma with BRAF Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in FDA Approvals, Melanoma
Copiktra (Duvelisib) Approved for Relapsed or Refractory CLL, SLL, and Follicular Lymphoma
Lisa A. Raedler, PhD, RPh, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in FDA Approvals, Lymphoma
Daurismo (Glasdegib) Approved, in Combination with Low-Dose Cytarabine, for Newly Diagnosed Acute Myeloid Leukemia in Older Adults or Those Unfit for Intensive Chemotherapy
Loretta Fala, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in FDA Approvals, Leukemia
Erleada (Apalutamide) First Drug Approved by the FDA for Nonmetastatic Castration-Resistant Prostate Cancer
Loretta Fala, Medical Writer
2019 Fourth Annual Oncology Guide to New FDA Approvals published on June 5, 2019 in FDA Approvals, Prostate Cancer
Last modified: July 27, 2016